Clinical trials located in

Ioannina

Ioannina city is located in Greece. Currently, 20 clinical trials are being conducted in this city.

Ioannina, nestled in the heart of Epirus, Greece, is a city rich in history and culture. Founded by the Byzantine Emperor Justinian in the 6th century, it boasts a remarkable blend of Ottoman, Byzantine, and Jewish heritage. The city is renowned for its iconic Ioannina Castle, the oldest Byzantine fortress in Greece, and the enchanting islet on Lake Pamvotida, accessible only by boat, home to centuries-old monasteries. Ioannina is also celebrated for its silver craftsmanship, a tradition that dates back to the Ottoman era, contributing to its unique cultural tapestry.

  • CT-EU-00121567

    Study of Giredestrant and other drugs in patients with HER2-negative early breast cancer

    This study focuses on early stage breast cancer with estrogen receptor (ER)-positive and HER2-negative status. The study compares the effectiveness and safety of giredestrant with the physician’s choice of endocrine (hormonal) therapy.

    The study involves participants with histologically confirmed (histology is the study of tissues) early stage breast cancer in stages I to III, who are at medium to high risk. Patients must have had their primary breast tumor and axillary lymph nodes surgically removed.

    The aim is to evaluate how well giredestrant works compared to the standard hormonal therapy chosen by the physician in preventing the recurrence of cancer after treatment for early stage breast cancer. Giredestrant is administered orally once daily for 5 years.

    Both men and women may qualify for the study, provided they meet certain health and surgical criteria. This study also includes an additional substudy to explore the safety of combining giredestrant with abemaciclib in a selected group of participants.

    Giredestrant acts as an antagonist (blocking agent) to estrogen receptors, aiming to reduce the risk of cancer recurrence. Abemaciclib is an oral medication that inhibits the enzyme called cyclin-dependent kinase 4/6 (CDK4/6), which helps to stop the growth of cancer cells.

    The ultimate goal of the study is to determine whether giredestrant or its combination with abemaciclib can offer better treatment outcomes than the currently used hormonal therapies in preventing breast cancer recurrences.

    • Endocrine Therapy of Physician’s Choice
    • LHRH Agonist
    • Abemaciclib
    • Giredestrant
  • Study Comparing Asciminib and Nilotinib for Newly Diagnosed Chronic Myeloid Leukemia

    This study examines the effects and tolerance of two drugs, asciminib and nilotinib, for treating a specific type of leukemia called Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in its chronic phase. The participants are adults who have been newly diagnosed and have not received previous treatment for this condition. They will be randomly assigned to receive either asciminib or nilotinib. The study aims to see which drug is better tolerated and how effective they are. Throughout the study, participants will be monitored for any side effects and the progress of their treatment until they either experience significant side effects, the disease progresses, or they decide to stop the treatment. Follow-up checks will also be conducted after the treatment ends.

    • Asciminib
    • Nilotinib
  • Testing tozorakimab’s effect on chronic lung disease symptoms

    This study is all about testing a new drug, Tozorakimab, for people who have COPD – a lung disease that makes it difficult to breathe—and have had a bad flare-up in the past year. The researchers will give some people the new drug and some people a placebo (a dummy treatment) and see which works best. The drug is delivered in a shot under the skin, and all the people in the study will also keep taking their usual COPD medicines. The main things the researchers will be looking at are whether the new drug can reduce the number of flare-ups, improve quality of life (measured using a questionnaire), reduce the need for rescue medication and if it changes the results of breathing tests.

    • Tozorakimab
  • Study on new combination therapy for aggressive lymphoma

    This study is about a less common but severe form of cancer known as Diffuse Large B-Cell Lymphoma (DLBCL). It is testing if a new medication called epcoritamab, given with a mix of other commonly used cancer medicines, can help control the disease better. These other medicines include rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone, which are often collectively referred to as R-CHOP. The study includes about 900 adults from around the world who have recently been diagnosed with this type of lymphoma. They will be split into two groups. One group will get epcoritamab with R-CHOP and then continue with epcoritamab. The other group will get R-CHOP followed by rituximab. Doctors will carefully watch for changes in the disease and for any side effects. There will be many checks on health, including medical exams, blood tests, questionnaires, and monitoring of any side effects.

    • Prednisone
    • Vincristine
    • Doxorubicin
    • Epcoritamab
    • Cyclophosphamide
    • Rituximab
  • Study of the effectiveness of tanimilast in the treatment of pulmonary diseases

    A 52-week clinical trial is being conducted to investigate the effectiveness and safety of the new drug, known as Tanimilast (CHF6001), in people diagnosed with chronic bronchitis and chronic obstructive pulmonary disease (COPD). The primary aim of the study is to determine the effectiveness of CHF6001 administered as an addition to a standard COPD treatment regimen. Study participants will be randomly assigned to receive the study drug CHF6001 or a placebo, which will be taken concurrently with their existing COPD therapy. Key measurements in the study include monitoring the frequency and severity of COPD exacerbations, which are episodes of significantly worsening symptoms. Additionally, the study will assess changes in participants’ lung function and overall quality of life. Typically eligible for the study are adults who are 40 years of age or older, have a documented history of COPD and chronic bronchitis, and are current or former smokers. In particular, the study is of interest to people who have experienced at least one COPD exacerbation in the year preceding the study.

    • Tanimilast/CHF6001
    • Roflumilast
  • Testing nivolumab alone and with Ipilimumab for advanced bowel cancer

    This study is about testing different treatments for a type of advanced bowel cancer called Metastatic Colorectal Cancer, which offers certain genetic features (called MSI-H or dMMR). The study aims to compare the efficacy of treatment approaches for cancer. One involves the use of the drug Nivolumab alone, and the other combines Nivolumab with another drug called Ipilimumab. These approaches will be compared against the benefits of conventional chemotherapy, as determined by the treating physician. The study will evaluate factors such as the extent of cancer shrinkage and the duration of growth inhibition.

    • Nivolumab
    • Ipilimumab
    • Fluorouracil
    • Leucovorin
    • Bevacizumab
    • Cetuximab
    • Irinotecan
    • Oxaliplatin
  • Evaluating datopotamab deruxtecan & pembrolizumab for advanced lung cancer

    This study compares two treatments for people with a type of lung cancer called ‘non-small cell lung cancer’ that has spread to other parts of the body. It tests whether combining a drug called datopotamab deruxtecan (Dato-DXd) with pembrolizumab works better than using pembrolizumab alone. Aimed at patients with non-small cell lung cancer (NSCLC) who haven’t had previous systemic therapy, it’s especially for those with high PD-L1 tumor expression.

    • Datopotamab deruxtecan
    • Pembrolizumab
  • Comparison of drug combinations in the treatment of advanced lung cancer

    This trial studies a first-line treatment involving Dato-DXd plus pembrolizumab compared to pembrolizumab alone in subjects with advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations. The goal is to evaluate the effectiveness and safety of this combined strategy. Target volunteers must not have received any treatments for their advanced or metastatic NSCLC. Participation includes receiving either the combined treatment or pembrolizumab alone. Regular health checks will monitor if any changes or adverse events occur during the trial.

    • Dato-DXd
    • Pembrolizumab
  • Examining new drug combo vs. standard treatment with pembrolizumab for advanced lung cancer

    This trial is examining if a combination of two medications, Dato-DXd and pembrolizumab, could be superior to using pembrolizumab alone in treating a type of lung cancer known as metastatic non-small cell lung cancer (NSCLC). Participants will include those who have advanced or spread NSCLC and haven’t had systemic treatment for it. The team will be comparing whether the combination treatment can help patients live longer or keep the cancer from growing for a longer period. One group of participants will get pembrolizumab on its own, while another will get both Dato-DXd and pembrolizumab. An important part of the study will assess how the treatment affects the patient’s symptoms and quality of life.

    • Datopotamab deruxtecan
    • Pembrolizumab
  • Research on plitidepsin effectiveness in treating COVID-19

    This research study aims to investigate the benefits and safety of a drug called plitidepsin for COVID-19 patients who have a weakened immune system and require hospital care. The study will administer the drug to some patients, while others will receive standard care, allowing researchers to assess whether plitidepsin can reduce death rates in this specific population. Throughout the study, close monitoring will be conducted to observe any changes, including side effects, serious incidents, or the necessity to discontinue the treatment.

    • Plitidepsin
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Assessing olpasiran treatment for heart disease and elevated cholesterol

    Tests named ‘OCEAN(a)’ are being conducted, focusing on a medication called ‘olpasiran’. Put simply, the potential of this medication in preventing serious heart episodes in individuals with Atherosclerotic Cardiovascular Disease and an elevated level of a fat protein, Lipoprotein(a), is under examination. The effect of a harmless, dummy pill (placebo) is compared to that of the actual medication, olpasiran, in individuals with these conditions. The primary goal is to determine whether olpasiran can reduce the risk of death due to heart disease, occurrence of heart attacks, or the necessity for sudden surgery to clear blocked heart vessels.

    • Olpasiran
  • Testing astegolimab’s effectiveness in chronic obstructive pulmonary disease patients

    A clinical research study is being conducted to examine the efficacy and safety of a novel treatment known as astegolimab in the management of Chronic Obstructive Pulmonary Disease (COPD). The study is particularly focused on individuals with a history of COPD who are either current or former smokers and have experienced frequent exacerbations. Within the scope of this study, astegolimab’s therapeutic potential is being compared to that of a placebo. Participants enrolled in the trial will be administered the study medication at intervals of either every 2 or 4 weeks. Key parameters under evaluation include the frequency of COPD exacerbations, variations in the quality of life of the participants, and changes in lung function over the course of the study. The study aims to contribute valuable data to medical research, particularly in understanding the treatment dynamics of astegolimab in COPD management.

    • Astegolimab
  • Testing the effect and safety of tanimilast for COPD patients

    This study is a year-long experiment where the researchers will test the effectiveness and safety of two doses of a new drug called tanimilast. Tanimilast is added to the usual treatment for people with two lung conditions: COPD and Chronic Bronchitis. The drug will be tested and compared with a group that will take a placebo, a substance with no effect. The main aim is to see if tanimilast helps control the worsening of symptoms in COPD patients. These worsening instances are known as ‘exacerbations’ and can range in severity. Some might require extra medication.

    • Tanimilast/CHF6001
  • Testing efavaleukin alfa’s effect on moderately to severely active ulcerative colitis

    This trial is about a drug named efavaleukin alfa, which might be helpful for people suffering from ulcerative colitis. Participants will either receive one of three doses of this drug or placebo for 12 weeks. If the treatment works, participants can choose to continue it for up to 52 weeks. If initially received placebo didn’t work, treatment will be switched to efavaleukin alfa.

    • Efavaleukin alfa
  • Testing new drug for lung fibrosis safety & effectiveness

    This study explores new treatment options for idiopathic pulmonary fibrosis (IPF) with a new drug called BMS-986278. The main goal is to thoroughly evaluate the effectiveness and safety of BMS-986278 in the treatment of IPF. During the study, participants will receive the drug under close supervision, allowing researchers to collect valuable data on its effects and potential benefits. This careful monitoring also ensures the safety and well-being of each participant. Participating in this study may provide insightful data on how IPF symptoms respond to this new treatment.

    • BMS-986278- new potential medication for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF)
  • Testing the safety and effectiveness of a new drug in the treatment of pulmonary fibrosis

    This study is testing a new drug called BMS-986278 for a lung disease called progressive pulmonary fibrosis. This condition causes the lungs to become increasingly scarred over time, making breathing difficult. Randomly assigned participants will receive either the real drug or a fake drug (placebo) that doesn’t work. No one will know who gets what, not even doctors. The goal is to see if this new drug helps slow the progression of the disease, prevent patients from having to be hospitalized and/or increase their chances of survival. These outcomes will be measured by tracking breathing tests, any sudden, serious worsening of the disease, any hospital stays related to lung disease, and any deaths from any cause.

    • BMS-986278- new potential medication for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF)
  • Advancing treatment options for Idiopathic Pulmonary Fibrosis

    This clinical trial examines the effectiveness of BMS-986278 in people with Idiopathic Pulmonary Fibrosis (IPF). Involving over 1,000 participants, the trial is designed to assess the drug’s efficacy, safety, and tolerability. Participants will receive either the study drug or a placebo. Key measures include changes in lung function, quality of life, and exercise capacity. This research could offer important insights for treating IPF, a condition that affects lung tissue.

    • BMS-986278- new potential medication for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF)
  • Comparatively studying drug combinations for multiple myeloma treatment

    This study is testing different combinations of drugs used to treat a cancer called multiple myeloma. Patients will receive one of two sets of treatments. One set contains a medicine called belantamab mafodotin combined with two others, while the second set contains the same two medicines but with another third medicine called bortezomib. The main goal is to determine which of these combinations is more effective in patients with multiple myeloma, especially those for whom other treatments have failed. Researchers will measure how many participants see the disease go away, how long the disease is kept in check, and overall survival rates. In addition, they will use questionnaires to assess your quality of life and understand the range of symptoms or problems you may experience during the examination.

    • Belantamab mafodotin
    • Pomalidomide
    • Dexamethasone
    • Bortezomib

See more clinical trials in other cities in Greece:

.